View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2013	Feb. 15, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 559,000,000
Entity Common Stock, Shares Outstanding		105,581,111
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 44,077,751	$ 6,754,485
Accounts receivable, net	16,092,836	7,653,561
Inventory, net	3,880,776	3,022,784
Prepaid expenses	1,337,408	657,961
Total current assets	65,388,771	18,088,791
Property and equipment, net of accumulated depreciation	4,086,106	1,071,625
Goodwill	4,040,443	4,040,443
Intangible assets, net of accumulated amortization	11,178,573	11,911,749
Other assets	0	70,000
Total assets	84,693,893	35,182,608
Current liabilities:
Accounts payable	2,490,531	1,251,684
Accrued compensation	5,588,811	2,753,237
Accrued expenses	1,405,974	990,697
Other current liabilities	122,551	21,583
Total current liabilities	9,607,867	5,017,201
Earn-out liability payable in MiMedx common stock	0	5,792,330
Convertible Senior Secured Promissory Notes, net	0	4,012,442
Other liabilities	1,517,956	353,333
Total liabilities	11,125,823	15,175,306
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 130,000,000 shares authorized; 104,425,614 issued and 104,375,614 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 2012	104,426	88,423
Additional paid-in capital	147,284,219	89,627,601
Treasury stock (50,000 shares at cost)	(25,000)	(25,000)
Accumulated deficit	(73,795,575)	(69,683,722)
Total stockholders' equity	73,568,070	20,007,302
Total liabilities and stockholders' equity	$ 84,693,893	$ 35,182,608

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	104,425,614	88,423,169
Common stock, shares outstanding (in shares)	104,375,614	88,373,169
Treasury stock, shares (in shares)	50,000	50,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]
Net sales	$ 59,180,734	$ 27,053,773	$ 7,760,446
Cost of sales	9,328,114	5,188,378	3,357,909
Gross margin	49,852,620	21,865,395	4,402,537
Operating expenses:
Research and development expenses	4,843,457	2,884,546	2,976,313
Selling, general and administrative expenses	46,225,657	19,590,446	9,845,529
Impairment of intangible assets	368,102	1,798,495	0
Fair value adjustment of earn-out liability	0	1,567,050	5,803
Amortization of intangible assets	1,053,971	1,380,241	1,335,908
Operating income (loss)	(2,638,567)	(5,355,383)	(9,761,016)
Other income (expense), net
Amortization of debt discount	(1,328,439)	(1,714,101)	(315,152)
Interest expense, net	(45,233)	(592,892)	(117,818)
Income (loss) before income tax provision	(4,012,239)	(7,662,376)	(10,193,986)
Income tax provision	(99,614)	0	0
Net income (loss)	$ (4,111,853)	$ (7,662,376)	$ (10,193,986)
Net income (loss) per common share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.09)	$ (0.14)
Weighted average shares outstanding - basic and diluted (in shares)	96,285,504	81,646,295	72,450,337

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred Stock Series A	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Balance at Dec. 31, 2010	$ 6,100,528	$ 0	$ 64,382	$ 57,888,506	$ (25,000)	$ (51,827,360)
Balance (in shares) at Dec. 31, 2010		0	64,381,910
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,659,083	$ 0	$ 0	1,659,083	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	295,753	$ 0	$ 490	295,263	0	0
Exercise of stock options (in shares)		0	490,000
Sale or offering of common stock and warrants, net of costs and expenses	3,730,587	$ 0	$ 3,779	3,726,808	0	0
Sale or offering of common stock and warrants, net of costs and expenses (in shares)		0	3,778,321
Common stock issued for the conversion of convertible debt	$ 406,663	$ 0	$ 406	406,257	0	0
Common stock issued for the conversion of convertible debt (in shares)	406,664	0	406,664
Common stock issued for the acquisition of Surgical Biologics, LLC	$ 7,087,500	$ 0	$ 5,250	7,082,250	0	0
Common stock issued for the acquisition of Surgical Biologics, LLC (in shares)		0	5,250,000
Beneficial conversion feature recognized on convertible debt	2,715,552	$ 0	$ 0	2,715,552	0	0
Warrants issued in conjunction with convertible promissory notes	14,885	0	0	14,885	0	0
Common stock issued for accrued director fees	0
Common stock issued for earn-out liability	0
Discount on beneficial conversion feature	$ 80,000	0	0	80,000	0	0
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	$ 0
Net income (loss)	(10,193,986)	0	0	0	0	(10,193,986)
Balance at Dec. 31, 2011	11,896,565	$ 0	$ 74,307	73,868,604	(25,000)	(62,021,346)
Balance (in shares) at Dec. 31, 2011		0	74,306,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,538,721	$ 0	$ 0	2,538,721	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	1,052,668	$ 0	$ 844	1,051,824	0	0
Exercise of stock options (in shares)		0	843,863
Common stock issued for the conversion of convertible debt	0
Exercise of warrants	6,001,063	$ 0	$ 7,960	5,993,103	0	0
Exercise of warrants (in shares)		0	7,959,767
Repurchase warrants	(568)	$ 0	$ 0	(568)	0	0
Repurchase warrants (in shares)		0	0
Cashless exercise of warrants	0	$ 0	$ 216	(216)	0	0
Cashless exercise of warrants (in shares)		0	216,085
Common stock issued for accrued director fees	184,653	$ 0	$ 167	184,486	0	0
Common stock issued for accrued director fees (in shares)		0	167,086
Common stock issued for earn-out liability	$ 3,185,223	$ 0	$ 2,632	3,182,591	0	0
Common stock issued for earn-out liability (in shares)	2,632,576	0	2,632,576
Discount on beneficial conversion feature	$ 514,456	$ 0	$ 0	514,456	0	0
Common stock issued for acquisition note	$ 893,267	$ 0	$ 893	892,374	0	0
Common stock issued for acquisition note (in shares)	893,267	0	893,267
Conversion of line of credit with related party	$ 1,403,630	$ 0	$ 1,404	1,402,226	0	0
Conversion of line of credit with related party (in shares)	1,403,630	0	1,403,630
Net income (loss)	$ (7,662,376)	$ 0	$ 0	0	0	(7,662,376)
Balance at Dec. 31, 2012	20,007,302	$ 0	$ 88,423	89,627,601	(25,000)	(69,683,722)
Balance (in shares) at Dec. 31, 2012		0	88,423,169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,009,176	$ 0	$ 0	6,009,176	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	$ 1,981,418	$ 0	$ 1,959	1,979,459	0	0
Exercise of stock options (in shares)	1,958,674	0	1,958,674
Sale or offering of common stock and warrants, net of costs and expenses	$ 36,509,810	$ 0	$ 5,750	36,504,060	0	0
Sale or offering of common stock and warrants, net of costs and expenses (in shares)		0	5,750,000
Common stock issued for the conversion of convertible debt	$ 5,272,004	$ 0	$ 5,272	5,266,732	0	0
Common stock issued for the conversion of convertible debt (in shares)	5,272,004	0	5,272,004
Exercise of warrants	$ 2,107,883	$ 0	$ 1,844	2,106,039	0	0
Exercise of warrants (in shares)		0	1,844,352
Common stock issued for accrued director fees	0
Common stock issued for earn-out liability	$ 5,792,330	$ 0	$ 1,175	5,791,155	0	0
Common stock issued for earn-out liability (in shares)	1,174,915	0	1,174,915
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	$ 0
Issuance of restricted stock	0	$ 0	$ 3	(3)	0	0
Issuance of restricted stock (in shares)		0	2,500
Net income (loss)	(4,111,853)	$ 0	$ 0	0	0	(4,111,853)
Balance at Dec. 31, 2013	$ 73,568,070	$ 0	$ 104,426	$ 147,284,219	$ (25,000)	$ (73,795,575)
Balance (in shares) at Dec. 31, 2013		0	104,425,614

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	12 Months Ended
	Dec. 31, 2011 USD ($)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock and warrants, net of offering cost	$ 47,733
5% Convertible Senior Secured Promissory Note
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible note	5.00%

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income (loss)	$ (4,111,853)	$ (7,662,376)	$ (10,193,986)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	637,246	465,367	446,502
Loss on fixed asset disposal	36,800	0	0
Amortization of intangible assets	1,053,971	1,380,241	1,335,908
Impairment of intangible assets	368,102	1,798,495	0
Amortization of debt discount and deferred financing costs	1,328,439	1,714,101	315,152
Share-based compensation	6,009,176	2,538,721	1,659,083
Change in fair value of earn-out liability	0	1,567,050	5,803
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(8,439,275)	(5,761,642)	(1,208,456)
Inventory	(857,992)	(2,310,182)	(253,942)
Prepaid expenses	(706,683)	(466,060)	(70,980)
Other assets	70,000	96,657	(80,375)
Accounts payable	1,208,747	(81,112)	732,938
Accrued compensation	2,835,574	2,354,888	194,934
Accrued expenses	352,881	605,856	328,379
Accrued interest	(41,641)	387,896	107,886
Other liabilities	(28,969)	40,840	16,383
Net cash flows from operating activities	(285,477)	(3,331,260)	(6,664,771)
Cash flows from investing activities:
Purchases of equipment	(2,336,517)	(636,502)	(486,091)
Cash paid for acquisition, net of cash acquired of $33,583	0	0	(466,417)
Proceeds from grant	0	0	250,000
Patent application costs	(688,897)	0	0
Net cash flows from investing activities	(3,025,414)	(636,502)	(702,508)
Cash flows from financing activities:
Proceeds from exercise of stock options	1,981,418	1,052,668	295,753
Proceeds from exercise of warrants	2,107,883	6,001,063	0
Proceeds from Senior Secured Promissory Notes	0	0	5,000,000
Proceeds from Line of Credit with related party	0	0	1,300,000
Proceeds from sale of common stock and warrants and common stock with registration rights, net	0	0	3,730,587
Proceeds from public offering, net of expenses	36,602,306	0	0
Repayment of Line of Credit	0	0	(99,000)
Repayment of Note Payable	0	0	(88,657)
Repayment of convertible debt related to acquisition	0	(427,126)	0
Principal payments of equipment leases	(57,450)	(16,116)	0
Repurchase of warrants	0	(568)	0
Net cash flows from financing activities	40,634,157	6,609,921	10,138,683
Net change in cash	37,323,266	2,642,159	2,771,404
Cash and cash equivalents, beginning of period	6,754,485	4,112,326	1,340,922
Cash and cash equivalents, end of period	$ 44,077,751	$ 6,754,485	$ 4,112,326

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	Dec. 31, 2011 USD ($)
Statement of Cash Flows [Abstract]
Acquisition, cash acquired	$ 33,583

Nature of Business	12 Months Ended
Nature of Business	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Our biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, and device technology CollaFix^™ . The Company is focused primarily on the United States but will pursue other individual markets based upon the specific opportunity. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., SpineMedica, LLC, and MiMedx Tissue Services, LLC, formerly known as Surgical Biologics, LLC. All significant inter-company balances and transactions have been eliminated.

Reclassifications

Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation.

Segment Reporting

ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2013, the Company had cash and cash equivalents of approximately $43,600,000 in excess of the insured amounts.

The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from its relationships with two of its distributors, AvKARE, Inc. which sells our products to the Federal government and another distributor that sells our products in certain defined Territories. For the years ended December 31, 2013, 2012 and 2011, AvKARE revenue was 56%, 40%, and 0% of total revenue, respectively. Related receivables for the same time periods were 55%, 53%, and 0%, of total accounts receivable, respectively. For the years ended December 31, 2013, 2012 and 2011, the other distributor's revenue was 10%, 21%, and 19% of total revenue, respectively. Related receivables for the same time periods were 12%, 25%, and 33% of total accounts receivable, respectively.

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

Inventories

Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes upon work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets

Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. For goodwill, the Company performs a two-step impairment test. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives

The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.

Our impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.

During the fourth quarter we chose to discontinue the HydroFix^® product line. This action resulted in an impairment charge of approximately $368,000 related to the Licenses for SaluMedica LLC, Spine Repair and Polyvinyl Alcohol Cryogel. This item is included in our Statement of Operations as of for the year ended December 31, 2013. An impairment charge of approximately $1,800,000 had previously been booked in 2012.

Property and Equipment

Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally five to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 5 and 15 for further information regarding capital leases, operating leases and rent expense.

Patent Costs

The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $690,000 of patent costs during 2013. There were no patent costs capitalized in 2012 or 2011.

Impairment of Long-lived Assets

The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized. During the fourth quarter of 2013, we chose to discontinue the HydroFix® product line. This action resulted in a disposal loss of approximately $30,000. This item is included in our Consolidated Statements of Operations for the year ended December 31, 2013, as Selling, General and Administrative expenses.

Grant Income

The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State. In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company has recorded the $250,000 as a reduction of Selling, General and Administrative expenses in the accompanying Consolidated Statements of Operations. Previously, this amount was recorded as Deferred Grant Income and was included in Other Liabilities per ASC 450-30 Gain Contingencies.

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

According to ASC470-20 "Debt With Conversion and Other Options", proceeds from the sale of convertible debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.

Revenue Recognition

The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that included the enactment date. Valuation allowances are recorded for deferred tax assets when the recoverability of such assets is not deemed more likely than not.

Uncertain Tax Positions

Tax positions are evaluated in a two-step process. The Company first determines whether it is more likely than not that a tax position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is more than 50% likely of being realized upon ultimate settlement. The Company classifies gross interest and penalties and unrecognized tax benefits that are not expected to result in payment or receipt of cash within one year as non-current liabilities in the Consolidated Balance Sheets.

Share-based Compensation

The Company follows the provisions of ASC topic 718 “Compensation — Stock compensation”, which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options and warrants). All awards are amortized on a straight-line basis over their vesting terms.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s capital leases approximates its carrying value based upon current rates available to the Company.

Fair Value Measurements

The Company records certain financial instruments at fair value, including: cash equivalents and contingent consideration. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2013, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets; and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.

The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate.

Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates "ASUs". For the year ended December 31, 2013, and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Liquidity and Management's Plans	12 Months Ended
Liquidity and Management's Plans	Dec. 31, 2013
Liquidity and management's plans [Abstract]
Liquidity and Management's Plans	Liquidity and Management's Plans As of December 31, 2013, the Company had approximately $44,100,000 of cash and cash equivalents. The Company reported total current assets of approximately $65,400,000 and current liabilities of approximately $9,600,000. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

Inventories

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following items as of December 31, 2013 and 2012:



	December 31,
	2013			2012
Raw materials	$	202,414		$	233,747
Work in process	2,951,704			1,598,537
Finished goods	1,048,886			1,349,121
Inventory, gross	4,203,004			3,181,405
Reserve for obsolescence	(322,228		)	(158,621		)
Inventory, net	$	3,880,776		$	3,022,784

Property and Equipment

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following as of December 31, 2013 and 2012:



	December 31,
	2013			2012
Leasehold improvements	$	2,319,928		$	1,022,230
Lab and clean room equipment	2,025,263			1,887,645
Furniture and equipment	1,240,466			431,563
Construction in Progress	802,319			10,027
Property and equipment, gross	6,387,976			3,351,465
Less accumulated depreciation	(2,301,870		)	(2,279,840		)
Property and equipment, net	$	4,086,106		$	1,071,625

Included in property and equipment is approximately $440,000 of capital leases. The corresponding liability is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of our new facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease.

Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was approximately $637,000, $465,000, and $447,000, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible Assets and Royalty Agreement

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Royalty Agreement

Intangible assets are summarized as follows:



		December 31,
		2013			2012
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b) (c) (d)	10 years	$	6,075,000		$	6,075,000
Patents & Know How (d)	14 years	7,798,910			7,690,000
Customer & Supplier Relationships (d)	14 years	3,761,000			3,761,000
Tradenames & Trademarks (d)	indefinite	1,008,000			1,008,000
In Process Research & Development (d)	indefinite	25,000			25,000
Patents in Process (e)	indefinite	579,987			—
Total		19,247,897			18,559,000
Less Accumulated amortization and impairment charges		(8,069,324		)	(6,647,251		)
Net		$	11,178,573		$	11,911,749

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2013, this license had a remaining net book value of approximately $309,000.

(b)

On September 1, 2005, we acquired a license from SaluMedica, LLC (SaluMedica) in the original amount of $2,399,000 for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In 2012, we booked an impairment charge related to this asset of $851,676. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix^® product line and fully impaired the asset. There was no charge to Operations as the asset was fully amortized.

(c)

On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel in the original amount of $2,667,000. In 2012, we booked an impairment charge related to this asset of $946,819. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix^® product line and fully impaired the asset. This resulted in an impairment charge of $368,102 which is included in the Company's Statement of Operations.

(d)

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2013 an additional $108,910 of costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.


(e)	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Amortization expense for the years ended December 31, 2013, 2012, and 2011, was approximately $1,054,000, $1,380,000, and $1,336,000, respectively.

Expected future amortization of intangible assets as of December 31, 2013, is as follows:



	Estimated
	Amortization
Year ending December 31,	Expense
2014	$	923,935
2015	923,935
2016	923,935
2017	834,302
2018	824,335
Thereafter	5,740,131
	$	10,170,573

Long-Term Debt

12 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

Long-Term Debt

The following table summarizes our long-term debt:



	December 31, 2013		December 31, 2012
$5,000,000 Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013, if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
Total debt	—		5,313,645
Less unamortized debt discount	—		(1,301,203		)
Less current portion	—		—
Long-term portion	$	—	$	4,012,442

(a)

Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052, which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Senior Secured Promissory Notes

From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000. The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.

In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. The warrants expire in 5 years. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.

During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000. In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the Chief Executive Officer’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013.

Line of Credit

On May 17, 2013, the Company and Bank of America, N.A. (the “Lender”) entered into a Loan Agreement (the “Loan Agreement”). The Loan Agreement provides the Company with a secured revolving line of credit (the “Revolving Line of Credit”) of up to $3,000,000, and includes a sub-limit of up to $1,000,000 for the issuance of letters of credit. The Revolving Line of Credit is secured by the Company's accounts receivable and inventory. The Company intends to utilize the Revolving Line of Credit for general corporate purposes. As of the date of this filing, the Company has not made any draws under the Revolving Line of Credit.

Accrued interest with respect to principal amounts outstanding under the Loan Agreement is payable in arrears on a monthly basis calculated at the rate of LIBOR plus two percent (2%). The principal amount outstanding under the Loan Agreement and any accrued and unpaid interest are due no later than May 1, 2014, and the Revolving Line of Credit is subject to certain prepayment penalties upon early termination of the Revolving Line of Credit. The Loan Agreement is subject to renewal by the lender at the end of the term.

The Loan Agreement contains covenants that limit under certain circumstances the ability of the Company to, among other things, merge with or acquire other entities, incur new liens, incur additional indebtedness, sell assets outside of the ordinary course of business, make loans, advances or other extensions of credit or engage in any business activities substantially different from the Company's current business without the Lender's consent. The Loan Agreement also requires the Company to maintain certain financial covenants, including a minimum funded debt to adjusted EBITDA ratio and a minimum fixed charge coverage ratio. The Company is in compliance with these covenants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Net Income (loss) Per Share

12 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

Net Income (loss) Per Share

Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method. For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share:



	Year Ended December 31,
	2013			2012			2011
Net income (loss)	$	(4,111,853	)	$	(7,662,376	)	$	(10,193,986	)
Denominator for basic earnings per share - weighted average shares	96,285,504			81,646,295			72,450,337
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—			—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	96,285,504			81,646,295			72,450,337
Income (loss) per common share - basic and diluted	$	(0.04	)	$	(0.09	)	$	(0.14	)


(a)	Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:



	Year Ended December 31,
	2013	2012	2011
Outstanding Stock Options	15,375,960	13,614,135	10,333,583
Outstanding Warrants	1,284,816	3,129,168	9,388,817
Convertible Debt, promissory notes	—	5,313,645	5,007,732
Convertible Line of Credit with Related Party	—	—	1,342,726
Convertible Debt, Acquisition	—	—	1,299,315
	16,660,776	22,056,948	27,372,173

Common Stock Placements	12 Months Ended
Common Stock Placements	Dec. 31, 2013
Stockholders' Equity Note [Abstract]
Common Stock Placements	Common Stock Placements Public Offering of Common Stock In December of 2013, the Company completed a public offering the 'Offering” of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from The Offering net of underwriting expenses of the Offering were $36,704,000. In addition, we incurred approximately $194,000 in various legal fees for services related to The Offering. We intend to use the net proceeds from The Offering for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products, although we currently have no agreements or commitments with respect to any such investment or acquisition. Each of our executive officers and directors, has agreed that, subject to certain exceptions, during the period ending 90 days after December 9, 2013, which we refer to as the restricted period, without the prior consent of Canaccord Genuity Inc., (the lead underwriter for The Offering) not to directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of any shares of common stock or any securities that may be converted into or exchanged for any shares of our common stock, enter into any swap or other arrangement that transfers to another person, in whole or in part, any of the economic consequences of ownership of our common stock. The foregoing restrictions do not apply with respect to an aggregate of 150,000 shares of common stock held by certain entities in which our Chairman and Chief Executive Officer possesses sole voting and investment control.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Equity

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity

Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2013, totaled 375,000. On March 6, 2013, the Board of Directors approved 6,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock which can be issued under the 2006 Plan to 22,500,000 at December 31, 2013. The shareholders approved the increase on May 9, 2013.

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2013	13,614,135		$	1.42
Granted	4,021,000		$	5.31
Exercised	(1,958,674	)	$	1.01
Unvested options forfeited	(265,002	)	$	3.47
Vested options expired	(35,499	)	$	1.11
Outstanding at December 31, 2013	15,375,960		$	2.46	7.7	$	96,614,260
Vested at December 31, 2013	6,807,732		$	1.33	6.5	$	50,441,475

Vested or expected to vest at December 31, 2013 (a)	15,081,653		$	2.42	7.7	$	95,324,825


(a)	Includes forfeiture adjusted unvested shares.

The intrinsic value of the options exercised during the years ended December 31, 2013, 2012 and 2011 were approximately $8,864,115, $718,978, and $258,000, respectively.

The intrinsic value of options vested during the years ended December 31, 2013, 2012 and 2011 were approximately $3,351,000, $1,851,000, and $1,194,000. respectively.

Following is a summary of stock options outstanding and exercisable at December 31,



		2013
	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	1,225,935	4.0	$	0.65	1,225,935	$	0.65
$0.87 - $1.35	6,570,341	7.6	1.20		3,604,469	1.18
$1.40 - $2.29	1,571,700	6.1	1.66		1,321,698	1.66
$2.33 - $3.75	2,091,984	8.7	2.77		655,630	2.77
$3.95 - $6.02	3,435,500	9.3	5.13		—	—
$6.04 - $7.93	480,500	8.9	6.61		—	—
	15,375,960	7.7	$	2.46	6,807,732	$	1.33

A summary of the status of the Company’s unvested stock options as of December 31 is presented below:



	2013
Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2013	8,377,538		$	0.96
Granted	4,021,000		$	3.08
Cancelled/expired	(265,002	)	$	2.14
Vested	(3,565,308	)	$	0.94
Unvested at December 31, 2013	8,568,228		$	1.94

Total unrecognized compensation expense at December 31, 2013, was approximately $12,052,935 and will be charged to expense through February 2016.

The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2013	2012	2011
Expected volatility	61.41 - 64.77%	45.7 - 64.3%	57.3-58.1%
Expected life (in years)	6	6	6
Expected dividend yield	—	—	—
Risk-free interest rate	0.85 - 1.88%	0.62 - 1.77%	0.86 - 2.24%

The weighted-average grant date fair value for options granted during the years ended December 31, 2013, 2012 and 2011 were approximately $3.08, $1.07, and $0.63, respectively.

Restricted Stock Awards

Following is summary information for restricted stock awards for the years ended 2013 and 2012. There were no restricted stock awards in 2011 and prior years. Shares vest over a one to three year period. As of December 31, 2013, there was approximately $2,471,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.5 years.



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2011	—		—
Granted	7,500		$3.49
Vested	—		—
Unvested at December 31, 2012	7,500		$3.49
Granted	576,550		$5.55
Vested	(2,500	)	$3.49
Forfeited	(5,000	)	$6.60
Unvested at December 31, 2013	576,550		$5.53

For the years ended December 31, 2013, 2012, and 2011 the Company recognized stock-based compensation as follows:



	Year Ended December 31,
	2013		2012		2011
Cost of sales	$	279,215	$	97,970	$	98,366
Research and development	417,436		289,341		254,997
Selling, general and administrative	5,312,525		2,151,410		1,305,720
	$	6,009,176	$	2,538,721	$	1,659,083

Warrants

From time to time the Company has granted common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years.

Common Stock warrants activity and resulting balances for the years ended December 31, 2013, 2012, and 2011 are as follows:



	Number of Warrants		Weighted- Average Exercise Price per Warrant		Number of Contingent Warrants		Weighted- Average Exercise Price per Contingent Warrant
Warrants outstanding at January 1, 2011	6,003,924		$	1.21	1,252,990		$	0.01
Issued in connection with private placement of common stock	1,889,161		1.50		1,889,162		0.01
Issued in connection with convertible promissory notes	203,332		1.50		203,332		0.01
Issued in connection with line of credit with related party	—		—		650,000		0.01
Issued in connection with Senior Secured Promissory Notes	1,250,000		0.01		1,250,000		0.01
Placement agent	42,400		1.09		—		—
Warrants outstanding at December 31, 2011	9,388,817		$	1.00	5,245,484		$	0.01

Warrants outstanding at January 1, 2012	9,388,817		$	1.00	5,245,484		$	0.01
Warrants issued:
Vested contingent warrants related to private placement of common stock	1,672,743		0.01		(1,672,743	)	0.01
Vested contingent warrants related to line of credit with related party	325,000		0.01		(325,000	)	0.01
Contingent warrants voided	—		—		(3,247,741	)	0.01
Warrants exercised:
Contingent warrants related to convertible note	(1,249,750	)	0.01		—		—
Contingent warrants related to private placement of common stock	(1,608,802	)	0.01		—		—
Contingent warrants related to line of credit with related party	(325,000	)	0.01		—		—
Callable warrants	(3,288,733	)	1.50		—		—
Other	(1,703,568	)	0.63		—		—
Warrants expired	(10,000	)	1.00		—		—
Warrants redeemed for cashless exercises	(14,789	)	0.53		—		—
Repurchased callable warrants	(56,750	)	1.50		—		—
Warrants outstanding at December 31, 2012	3,129,168		$	1.04	—		$	—

Warrants outstanding at January 1, 2013	3,129,168		1.04		—		—
Warrants exercised:
Other	(1,844,352	)	1.14		—		—
Warrants outstanding at December 31, 2013	1,284,816		$	0.90	—		$	—

Warrants may be exercised in whole or in part by:


•	notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or

•

if permitted by the applicable warrant election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.

These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issuing a variable number of shares.

The warrants require that the Company deliver shares as part of a physical settlement or, if permitted by the applicable warrant a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.

All of our warrants are classified as equity as of December 31, 2013, December 31, 2012, and December 31, 2011.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax assets and liabilities are as follows:



	December 31,
	2013			2012
Deferred tax assets and liabilities:
Accrued liabilities	$	1,404,000		$	(125,000	)
Beneficial conversion feature on convertible financial instruments	—			(449,000		)
Intangible assets	1,021,000			1,117,000
Property and equipment	(507,000		)	89,000
R&D Credit Carryforward	1,369,000			1,407,356
Stock Compensation	2,151,000			213,000
Adjust accrued earn-out liability	—			567,947
Charitable Contributions	1,000			3,000
Patent fees	142,000			6,000
Net operating loss	14,663,000			15,539,000
Net deferred tax assets	$	20,244,000		$	18,368,303

Valuation allowance	(20,244,000		)	(18,368,303		)
	$	—		$	—

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:



	December 31,
	2013		2012
Federal statutory rate	34.00	%	34.00	%
State taxes, net of federal benefit	(2.48	)%	3.40	%
Permanent items & other	12.73	%	0.65	%
Valuation allowance	(46.73	)%	(38.05	)%
	(2.48	)%	—	%

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.

Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. At December 31, 2013, the Company had a valuation allowance of $20,244,000 recorded against the benefit of certain deferred tax assets. In assessing the recoverability of our deferred tax assets, we analyzed all evidence, both positive and negative. We considered, among other things, our deferred tax liabilities, our historical earnings and losses, projections of future income, and tax-planning strategies available to us in the relevant jurisdiction.

At December 31, 2013, we have income tax net operating loss ("NOL") carry forwards for federal and state purposes of $36,861,000 and $30,036,000, respectively. The Company has recorded a deferred tax asset for both federal and state income taxes of $12,533,000 and $2,130,000, respectively. If not utilized, the federal and state tax loss carry forwards will expire between 2027 and 2033.

The Company's net operating losses and credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. At this time the Company does not believe its carryforwards or credits will be materially impacted by such limitations.

In July 2006, the FASB issued Interpretation 48 (codified primarily in ASC 740), which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with Statement 109 (codified primarily in ASC 740). Interpretation 48 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of Interpretation 48 and in subsequent periods. As a result of the implementation, the Company has analyzed its tax positions and determined that no reserve is necessary at this time.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2013, the Company’s tax years for 2010, 2011 and 2012 are subject to examination by the tax authorities. As of December 31, 2013, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2010. Tax year 2009 was open as of December 31, 2012.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

12 Months Ended

Dec. 31, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental disclosure of cash flow and non-cash investing and financing activities

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows:



	Twelve Months Ended December 31,
	2013		2012		2011
Cash paid for interest	$	36,202	$	13,322	$	15,456
Income taxes paid	61,129		—		—
Purchases of equipment financed through capital leases	355,144		84,650		—
Stock issuance of 167,086 shares in lieu of Directors' fees	—		184,653		—
Deferred financing costs	27,236		20,449		—
Convertible Secured Promissory Notes issued in conjunction with the acquisition of Surgical Biologics	—		—		1,250,000
Warrants issued for placement fees associated with Senior Secured Promissory Notes	—		—		14,885
Beneficial conversion related to Note Payable with related party	—		—		80,000
Beneficial conversion related to convertible debt issued with regard to acquisition of Surgical Biologics	—		—		437,500
Beneficial conversion related to Line of Credit with related party	—		514,456		—
Stock issuance of 5,250,000 shares in conjunction with acquisition of Surgical Biologics	—		—		7,087,500
Stock issuance in connection of Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares for 2012	5,792,330		3,185,223		—
Stock issuance in exchange for convertible debt of 5,272,004 shares in 2013 and 406,664 shares in 2011	5,272,004		—		406,663
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		1,403,630		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		216		—
Stock issuance of 893,267 shares in payment of Convertible
Secured Promissory Notes related to acquisition of Surgical Biologics	—		893,267		2,278,052
Tenant improvement incentive	996,866		—		—
Legal fees paid for public offering	101,694		—		—
Legal fees related to public offering included in accounts payable	30,100		—		—
Legal fees related to public offering included in accrued expenses	62,396		—		—

Related Party Transactions

12 Months Ended

Dec. 31, 2013

Related Party Transactions

The Company has related party expense as described in the following table:



	December 31,
	2013		2012		2011
Office space lease (a)	$	70,141	$	48,182	$	41,000
Aircraft use (b)	—		—		1,100
Hybrid debt instrument (c)	—		—		3,232
Line of credit (d)	—		103,630		42,726
Convertible senior secured promissory notes (e)	—		50,000		4,507
	$	70,141	$	201,812	$	92,565


(a)	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO for $70,141 for 2013 $48,182 for 2012 and $41,000 for 2011, respectively


(b)	payments related to aircraft use from an entity owned by a former member of the Board of Directors


(c)	interest of $3,232 related to convertible promissory notes issued in October 2010 to the Chairman of the Board and CEO and two other members of the Board of Directors


(d)	interest of $103,630 for 2012 and $42,726 for 2011, respectively related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011


(e)	interest of $50,000 for 2012 and $4,507 for 2011, respectively related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

401k Plan	12 Months Ended
401k Plan	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
401k Plan	401k Plan The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $17,500 per year (annual limit for 2013). Employees age 50 or over in 2013 may make additional pre-tax contributions up to $5,500 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2013, 2012 and 2011.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Contractual Arrangements

In addition to the capital leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration.

The estimated annual lease payments are as follows:



Year ended December 31,
2014	$	869,841
2015	1,300,289
2016	1,339,418
2017	1,379,877
2018	1,421,135
Thereafter	119,581
	$	6,430,141

Rent expense for the years ended December 31, 2013, 2012 and 2011, was approximately $1,000,000, $485,000 and $488,000, respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit

As a condition of the leases for the Company's facilities we are obligated under standby letters of credit in the amount of approximately $525,000. These obligations are reduced at various times over the lives of the leases.

FDA Untitled Letter and Related Litigation

Initially, MiMedx processed its tissue allografts in only one form, which was a sheet form. In 2011, MiMedx introduced a micronized form of its sheet allografts.

The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. If an HCT/P meets the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”), no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required.

MiMedx believes that all of its tissue products qualify as 361 HCT/Ps. On August 28, 2013, however, the FDA issued an Untitled Letter alleging that the Company’s micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market the micronized products.

After a series of correspondence and conference calls and a meeting with FDA representatives, in December 2013, the FDA clarified the basis for its position regarding the micronized products. Specifically, the FDA explained its belief that “[c]ryo-milling cut, dehydrated amniotic/chorionic membrane results in a micron-sized powder and the loss of the tensile strength and elasticity that are essential characteristics of the original amniotic/chorionic tissue relating to its utility to function as a ‘physical membrane’ (i.e. covering, barrier).” For this reason, the Agency continues to believe that the micronized products are more than minimally manipulated and the products therefore are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company responded to the FDA that while it does not agree with the Agency’s position, it understands the Agency’s interest in further regulating this emerging technology. Accordingly, the Company has proposed to the FDA that it will pursue the Investigational New Drug (“IND”) and Biologics License Application (“BLA”) process for certain micronized products, and, in parallel, also proposed to enter into negotiations with the FDA on a plan to transition the micronized products to licensed biological products and continue to market the micronized products under specific conditions. The Company has also informed the FDA that it is ready to immediately commence discussions regarding this transition plan. There is no guarantee that the FDA will agree to a transition plan or allow us to continue to market our micronized products while we pursue one or more BLAs. If they do allow us to continue to market our micronized products, they may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (“cGMP”). It is also possible that we will be required to recall our micronized products Revenues from micronized products make up about 15% of projected revenues in 2014.

Following the publication of the Untitled Letter from the FDA regarding the Company’s injectable products in September 2013, the trading price of the Company’s stock dropped sharply and several purported class action lawsuits were filed against us and certain of our executive officers asserting violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s belief that FDA approval was not required to market its products, including its micronized products. These cases have now all been removed to, and consolidated in, the United States District Court for the Northern District of Georgia. By order dated December 9, 2013, the Court approved the appointment of a lead plaintiff and a lead counsel. A Consolidated Amended Class Action Complaint, containing substantially the same causes of action and claims for relief as the initial complaints, was filed on January 27, 2014. On February 26, 2014, we filed a Motion to Dismiss on various grounds. The plaintiffs' response to the Company's Motion to Dismiss is due March 28, 2014. The Company currently believes that the outcome of this litigation will not have a material adverse impact on our financial position or results of operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)



		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
NET SALES	2013	$	11,556,493		$	13,514,743		$	16,115,708		$	17,993,790
	2012	3,705,808			4,884,256			7,954,046			10,509,663
	2011	1,043,487			1,929,399			2,152,094			2,635,466

GROSS MARGIN	2013	$	9,651,473		$	11,316,261		$	14,002,270		$	14,882,616
	2012	2,746,953			3,769,330			6,528,710			8,820,402
	2011	333,370			1,084,458			1,265,584			1,719,125

NET INCOME (LOSS)	2013	$	(1,620,408	)	$	(757,389	)	$	(307,118	)	$	(1,426,938	)
	2012	(1,093,652		)	(744,069		)	(4,219,372		)	(1,605,283		)
	2011	(3,347,562		)	(2,503,505		)	(1,765,723		)	(2,577,196		)

NET INCOME (LOSS) PER COMMON SHARE - BASIC AND DILUTED	2013	$	(0.02	)	$	(0.01	)	$	—		$	(0.01	)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)
	2011	(0.05		)	(0.03		)	(0.02		)	(0.04		)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Schedule II - Valuation and Qualifying Accounts (Notes)

12 Months Ended

Dec. 31, 2013

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Schedule II Valuation and Qualifying Accounts



MIMEDX GROUP, INC. AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2013, 2012 and 2011

	Balance at Beginning of Year	Additions charged to Expense or Revenue	Deductions and write-offs		Balance at End of Year

For the Year ended December 31, 2013
Allowance for doubtful accounts	49,000	391,000	(33,000	)	407,000
Allowance for product returns	89,000	917,000	(791,000	)	215,000
Allowance for obsolescence	159,000	213,000	(50,000	)	322,000

For the Year ended December 31, 2012
Allowance for doubtful accounts	19,000	57,000	(27,000	)	49,000
Allowance for product returns	88,000	394,000	(393,000	)	89,000
Allowance for obsolescence	53,000	106,000	—		159,000

For the Year ended December 31, 2011
Allowance for doubtful accounts	21,000	58,000	(60,000	)	19,000
Allowance for product returns	39,000	189,000	(140,000	)	88,000
Allowance for obsolescence	29,000	30,000	(6,000	)	53,000

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Reclassifications

Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation.

Segment Reporting

Market Concentrations and Credit Risk

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

Inventories

Goodwill and Purchased Intangible Assets

Impairment of Intangible Assets with Finite Lives

Property and Equipment

Impairment of Long-lived Assets

Grant Income

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

Revenue Recognition

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

Uncertain Tax Positions

Share-based Compensation

Fair Value of Financial Instruments

Fair Value Measurements


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

Recently Issued Accounting Pronouncements

Inventories (Tables)

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Inventory

Inventories consisted of the following items as of December 31, 2013 and 2012:



	December 31,
	2013			2012
Raw materials	$	202,414		$	233,747
Work in process	2,951,704			1,598,537
Finished goods	1,048,886			1,349,121
Inventory, gross	4,203,004			3,181,405
Reserve for obsolescence	(322,228		)	(158,621		)
Inventory, net	$	3,880,776		$	3,022,784

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment consist of the following as of December 31, 2013 and 2012:



	December 31,
	2013			2012
Leasehold improvements	$	2,319,928		$	1,022,230
Lab and clean room equipment	2,025,263			1,887,645
Furniture and equipment	1,240,466			431,563
Construction in Progress	802,319			10,027
Property and equipment, gross	6,387,976			3,351,465
Less accumulated depreciation	(2,301,870		)	(2,279,840		)
Property and equipment, net	$	4,086,106		$	1,071,625

Intangible Assets and Royalty Agreement (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets activity summary

Intangible assets are summarized as follows:



		December 31,
		2013			2012
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b) (c) (d)	10 years	$	6,075,000		$	6,075,000
Patents & Know How (d)	14 years	7,798,910			7,690,000
Customer & Supplier Relationships (d)	14 years	3,761,000			3,761,000
Tradenames & Trademarks (d)	indefinite	1,008,000			1,008,000
In Process Research & Development (d)	indefinite	25,000			25,000
Patents in Process (e)	indefinite	579,987			—
Total		19,247,897			18,559,000
Less Accumulated amortization and impairment charges		(8,069,324		)	(6,647,251		)
Net		$	11,178,573		$	11,911,749

(a)

(b)

(c)

(d)


(e)	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Estimated future amortization expense for intangible assets

Expected future amortization of intangible assets as of December 31, 2013, is as follows:



	Estimated
	Amortization
Year ending December 31,	Expense
2014	$	923,935
2015	923,935
2016	923,935
2017	834,302
2018	824,335
Thereafter	5,740,131
	$	10,170,573

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

Long-term Debt

The following table summarizes our long-term debt:



	December 31, 2013		December 31, 2012
$5,000,000 Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013, if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)	$	—	$	5,313,645
Total debt	—		5,313,645
Less unamortized debt discount	—		(1,301,203		)
Less current portion	—		—
Long-term portion	$	—	$	4,012,442

(a)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Net Income (loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share:



	Year Ended December 31,
	2013			2012			2011
Net income (loss)	$	(4,111,853	)	$	(7,662,376	)	$	(10,193,986	)
Denominator for basic earnings per share - weighted average shares	96,285,504			81,646,295			72,450,337
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—			—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	96,285,504			81,646,295			72,450,337
Income (loss) per common share - basic and diluted	$	(0.04	)	$	(0.09	)	$	(0.14	)


(a)	Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:

Summary of Antidilutive Securities

Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:



	Year Ended December 31,
	2013	2012	2011
Outstanding Stock Options	15,375,960	13,614,135	10,333,583
Outstanding Warrants	1,284,816	3,129,168	9,388,817
Convertible Debt, promissory notes	—	5,313,645	5,007,732
Convertible Line of Credit with Related Party	—	—	1,342,726
Convertible Debt, Acquisition	—	—	1,299,315
	16,660,776	22,056,948	27,372,173

Equity (Tables)

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options activity

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2013	13,614,135		$	1.42
Granted	4,021,000		$	5.31
Exercised	(1,958,674	)	$	1.01
Unvested options forfeited	(265,002	)	$	3.47
Vested options expired	(35,499	)	$	1.11
Outstanding at December 31, 2013	15,375,960		$	2.46	7.7	$	96,614,260
Vested at December 31, 2013	6,807,732		$	1.33	6.5	$	50,441,475

Vested or expected to vest at December 31, 2013 (a)	15,081,653		$	2.42	7.7	$	95,324,825


(a)	Includes forfeiture adjusted unvested shares.

Summary of stock options outstanding and exercisable

Following is a summary of stock options outstanding and exercisable at December 31,



		2013
	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	1,225,935	4.0	$	0.65	1,225,935	$	0.65
$0.87 - $1.35	6,570,341	7.6	1.20		3,604,469	1.18
$1.40 - $2.29	1,571,700	6.1	1.66		1,321,698	1.66
$2.33 - $3.75	2,091,984	8.7	2.77		655,630	2.77
$3.95 - $6.02	3,435,500	9.3	5.13		—	—
$6.04 - $7.93	480,500	8.9	6.61		—	—
	15,375,960	7.7	$	2.46	6,807,732	$	1.33

Unvested Stock Options Roll Forward

A summary of the status of the Company’s unvested stock options as of December 31 is presented below:



	2013
Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2013	8,377,538		$	0.96
Granted	4,021,000		$	3.08
Cancelled/expired	(265,002	)	$	2.14
Vested	(3,565,308	)	$	0.94
Unvested at December 31, 2013	8,568,228		$	1.94

Fair value of options valuation assumptions

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2013	2012	2011
Expected volatility	61.41 - 64.77%	45.7 - 64.3%	57.3-58.1%
Expected life (in years)	6	6	6
Expected dividend yield	—	—	—
Risk-free interest rate	0.85 - 1.88%	0.62 - 1.77%	0.86 - 2.24%

Restricted Stock Awards Roll Forward



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2011	—		—
Granted	7,500		$3.49
Vested	—		—
Unvested at December 31, 2012	7,500		$3.49
Granted	576,550		$5.55
Vested	(2,500	)	$3.49
Forfeited	(5,000	)	$6.60
Unvested at December 31, 2013	576,550		$5.53

Allocation of Share-based Compensation

For the years ended December 31, 2013, 2012, and 2011 the Company recognized stock-based compensation as follows:



	Year Ended December 31,
	2013		2012		2011
Cost of sales	$	279,215	$	97,970	$	98,366
Research and development	417,436		289,341		254,997
Selling, general and administrative	5,312,525		2,151,410		1,305,720
	$	6,009,176	$	2,538,721	$	1,659,083

Summary of warrants outstanding

Common Stock warrants activity and resulting balances for the years ended December 31, 2013, 2012, and 2011 are as follows:



	Number of Warrants		Weighted- Average Exercise Price per Warrant		Number of Contingent Warrants		Weighted- Average Exercise Price per Contingent Warrant
Warrants outstanding at January 1, 2011	6,003,924		$	1.21	1,252,990		$	0.01
Issued in connection with private placement of common stock	1,889,161		1.50		1,889,162		0.01
Issued in connection with convertible promissory notes	203,332		1.50		203,332		0.01
Issued in connection with line of credit with related party	—		—		650,000		0.01
Issued in connection with Senior Secured Promissory Notes	1,250,000		0.01		1,250,000		0.01
Placement agent	42,400		1.09		—		—
Warrants outstanding at December 31, 2011	9,388,817		$	1.00	5,245,484		$	0.01

Warrants outstanding at January 1, 2012	9,388,817		$	1.00	5,245,484		$	0.01
Warrants issued:
Vested contingent warrants related to private placement of common stock	1,672,743		0.01		(1,672,743	)	0.01
Vested contingent warrants related to line of credit with related party	325,000		0.01		(325,000	)	0.01
Contingent warrants voided	—		—		(3,247,741	)	0.01
Warrants exercised:
Contingent warrants related to convertible note	(1,249,750	)	0.01		—		—
Contingent warrants related to private placement of common stock	(1,608,802	)	0.01		—		—
Contingent warrants related to line of credit with related party	(325,000	)	0.01		—		—
Callable warrants	(3,288,733	)	1.50		—		—
Other	(1,703,568	)	0.63		—		—
Warrants expired	(10,000	)	1.00		—		—
Warrants redeemed for cashless exercises	(14,789	)	0.53		—		—
Repurchased callable warrants	(56,750	)	1.50		—		—
Warrants outstanding at December 31, 2012	3,129,168		$	1.04	—		$	—

Warrants outstanding at January 1, 2013	3,129,168		1.04		—		—
Warrants exercised:
Other	(1,844,352	)	1.14		—		—
Warrants outstanding at December 31, 2013	1,284,816		$	0.90	—		$	—

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows:



	December 31,
	2013			2012
Deferred tax assets and liabilities:
Accrued liabilities	$	1,404,000		$	(125,000	)
Beneficial conversion feature on convertible financial instruments	—			(449,000		)
Intangible assets	1,021,000			1,117,000
Property and equipment	(507,000		)	89,000
R&D Credit Carryforward	1,369,000			1,407,356
Stock Compensation	2,151,000			213,000
Adjust accrued earn-out liability	—			567,947
Charitable Contributions	1,000			3,000
Patent fees	142,000			6,000
Net operating loss	14,663,000			15,539,000
Net deferred tax assets	$	20,244,000		$	18,368,303

Valuation allowance	(20,244,000		)	(18,368,303		)
	$	—		$	—

Reconciliation of the Federal statutory income tax

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:



	December 31,
	2013		2012
Federal statutory rate	34.00	%	34.00	%
State taxes, net of federal benefit	(2.48	)%	3.40	%
Permanent items & other	12.73	%	0.65	%
Valuation allowance	(46.73	)%	(38.05	)%
	(2.48	)%	—	%

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)

12 Months Ended

Dec. 31, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows:



	Twelve Months Ended December 31,
	2013		2012		2011
Cash paid for interest	$	36,202	$	13,322	$	15,456
Income taxes paid	61,129		—		—
Purchases of equipment financed through capital leases	355,144		84,650		—
Stock issuance of 167,086 shares in lieu of Directors' fees	—		184,653		—
Deferred financing costs	27,236		20,449		—
Convertible Secured Promissory Notes issued in conjunction with the acquisition of Surgical Biologics	—		—		1,250,000
Warrants issued for placement fees associated with Senior Secured Promissory Notes	—		—		14,885
Beneficial conversion related to Note Payable with related party	—		—		80,000
Beneficial conversion related to convertible debt issued with regard to acquisition of Surgical Biologics	—		—		437,500
Beneficial conversion related to Line of Credit with related party	—		514,456		—
Stock issuance of 5,250,000 shares in conjunction with acquisition of Surgical Biologics	—		—		7,087,500
Stock issuance in connection of Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares for 2012	5,792,330		3,185,223		—
Stock issuance in exchange for convertible debt of 5,272,004 shares in 2013 and 406,664 shares in 2011	5,272,004		—		406,663
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		1,403,630		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		216		—
Stock issuance of 893,267 shares in payment of Convertible
Secured Promissory Notes related to acquisition of Surgical Biologics	—		893,267		2,278,052
Tenant improvement incentive	996,866		—		—
Legal fees paid for public offering	101,694		—		—
Legal fees related to public offering included in accounts payable	30,100		—		—
Legal fees related to public offering included in accrued expenses	62,396		—		—

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2013

Related party expense

The Company has related party expense as described in the following table:



	December 31,
	2013		2012		2011
Office space lease (a)	$	70,141	$	48,182	$	41,000
Aircraft use (b)	—		—		1,100
Hybrid debt instrument (c)	—		—		3,232
Line of credit (d)	—		103,630		42,726
Convertible senior secured promissory notes (e)	—		50,000		4,507
	$	70,141	$	201,812	$	92,565


(a)	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO for $70,141 for 2013 $48,182 for 2012 and $41,000 for 2011, respectively


(b)	payments related to aircraft use from an entity owned by a former member of the Board of Directors


(c)	interest of $3,232 related to convertible promissory notes issued in October 2010 to the Chairman of the Board and CEO and two other members of the Board of Directors


(d)	interest of $103,630 for 2012 and $42,726 for 2011, respectively related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011


(e)	interest of $50,000 for 2012 and $4,507 for 2011, respectively related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Estimated annual lease, royalty, and employment agreement expenses

The estimated annual lease payments are as follows:



Year ended December 31,
2014	$	869,841
2015	1,300,289
2016	1,339,418
2017	1,379,877
2018	1,421,135
Thereafter	119,581
	$	6,430,141

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Quarterly Financial Data (Unaudited)



		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
NET SALES	2013	$	11,556,493		$	13,514,743		$	16,115,708		$	17,993,790
	2012	3,705,808			4,884,256			7,954,046			10,509,663
	2011	1,043,487			1,929,399			2,152,094			2,635,466

GROSS MARGIN	2013	$	9,651,473		$	11,316,261		$	14,002,270		$	14,882,616
	2012	2,746,953			3,769,330			6,528,710			8,820,402
	2011	333,370			1,084,458			1,265,584			1,719,125

NET INCOME (LOSS)	2013	$	(1,620,408	)	$	(757,389	)	$	(307,118	)	$	(1,426,938	)
	2012	(1,093,652		)	(744,069		)	(4,219,372		)	(1,605,283		)
	2011	(3,347,562		)	(2,503,505		)	(1,765,723		)	(2,577,196		)

NET INCOME (LOSS) PER COMMON SHARE - BASIC AND DILUTED	2013	$	(0.02	)	$	(0.01	)	$	—		$	(0.01	)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)
	2011	(0.05		)	(0.03		)	(0.02		)	(0.04		)

Nature of Business (Details)	12 Months Ended
Nature of Business (Details)	Dec. 31, 2013 Business_Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
Significant Accounting Policies (Details)	Dec. 31, 2013 USD ($) distributor	Dec. 31, 2013 USD ($) distributor	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Jul. 31, 2010 USD ($)
Market Concentrations and Credit Risk [Line Items]
FDIC insured amount					$ 250,000
Cash and cash equivalents uninsured amount	$ 43,600,000	$ 43,600,000
Number of major customers \| distributor	2	2
Impairment of Intangible Assets with Finite Lives [Abstract]
Impairment of intangible assets	$ 368,000		$ 1,800,000
Impairment of Long-lived Assets [Abstract]
Impairment loss		$ 30,000
Grant Income [Abstract]
Proceeds from grant		0	0	$ 250,000
Patents
Impairment of Long-lived Assets [Abstract]
Intangible assets, net of accumulated amortization		$ 690,000	$ 0	$ 0
Minimum
Property and Equipment [Abstract]
Property and equipment estimated useful life		5 years
Maximum
Property and Equipment [Abstract]
Property and equipment estimated useful life		7 years
Revenue \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (in hundredths)		56.00%	40.00%	0.00%
Revenue \| CPM
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (in hundredths)		10.00%	21.00%	19.00%
Accounts Receivable \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (in hundredths)		55.00%	53.00%	0.00%
Accounts Receivable \| CPM
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (in hundredths)		12.00%	25.00%	33.00%

Liquidity and Management's Plans (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Liquidity and management's plans [Abstract]
Cash and cash equivalents	$ 44,077,751	$ 6,754,485	$ 4,112,326	$ 1,340,922
Total current assets	65,388,771	18,088,791
Total current liabilities	$ 9,607,867	$ 5,017,201

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 202,414	$ 233,747
Work in process	2,951,704	1,598,537
Finished goods	1,048,886	1,349,121
Inventory, gross	4,203,004	3,181,405
Reserve for obsolescence	(322,228)	(158,621)
Inventory, net	$ 3,880,776	$ 3,022,784

- Definition

The amount of the valuation account as of the balance sheet date which reduces the carrying amount of inventory to net realizable value; takes into consideration such factors as market value, excessive quantities based on expected sales, technological obsolescence, and shrinkage. May also provide for estimated product returns or price concessions pertaining to product cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=6386940&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 14
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 8, 9, 14
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 9
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

+ Details

Property and Equipment (Details) - USD ($)	12 Months Ended
Property and Equipment (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment [Line Items]
Property and equipment, gross	$ 6,387,976	$ 3,351,465
Less accumulated depreciation	(2,301,870)	(2,279,840)
Property and equipment, net	4,086,106	1,071,625
Depreciation expense	637,246	465,367	$ 446,502
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	2,319,928	1,022,230
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	2,025,263	1,887,645
Furniture and equipment
Property and equipment [Line Items]
Property and equipment, gross	1,240,466	431,563
Construction in Progress
Property and equipment [Line Items]
Property and equipment, gross	802,319	$ 10,027
Capital Leases
Property and equipment [Line Items]
Property and equipment, net	440,000
Leasehold improvements paid for by landlord
Property and equipment [Line Items]
Property and equipment, net	$ 1,000,000

Intangible Assets and Royalty Agreement (Details) - USD ($)

3 Months Ended

12 Months Ended

Mar. 31, 2008

Jan. 29, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 05, 2011

Finite-Lived Intangible Assets [Line Items]

Intangible Assets, Gross Carrying Value

$ 19,247,897

$ 18,559,000

Less Accumulated amortization and impairment charges

(8,069,324)

(6,647,251)

Intangible Assets, Net

11,178,573

11,911,749

Net book value

10,170,573

Impairment charge

368,000

1,800,000

Amortization of intangible assets

1,053,971

1,380,241

$ 1,335,908

Estimated future amortization expense [Abstract]

923,935

923,935

923,935

834,302

824,335

5,740,131

10,170,573

$ 10,170,573

Licenses

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^{[1],[2],[3],[4]}

10 years

Gross Carrying Value

^{[1],[2],[3],[4]}

6,075,000

$ 6,075,000

6,075,000

Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Finite-Lived Intangible Assets [Line Items]

Acquisition price

$ 996,000

Maximum time of approval

30 days

Contingent payments to licensor

$ 200,000

Contingent royalty to be paid to licensor (in hundredths)

3.00%

Annual royalty payment

$ 50,000

Net book value

$ 309,000

Estimated future amortization expense [Abstract]

Net book value

309,000

Licenses | SaluMedica, LLC

Finite-Lived Intangible Assets [Line Items]

Acquisition price

$ 2,399,000

Impairment charge

851,676

Licenses | HydroFix

Finite-Lived Intangible Assets [Line Items]

Acquisition price

$ 2,667,000

Impairment charge

368,102

946,819

Licenses | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

^{[1],[2],[3],[4]}

$ 13,000

Patents & Know How

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

7,798,910

$ 7,798,910

7,690,000

Patents & Know How | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

^[2]

7,690,000

Finite-Lived Intangible Assets, Costs

^[2]

$ 108,910

Customer & Supplier Relationships

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[2]

14 years

Gross Carrying Value

^[2]

3,761,000

$ 3,761,000

3,761,000

Customer & Supplier Relationships | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

^[2]

3,761,000

Tradenames & Trademarks

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives, Indefinite Lived

^[2]

indefinite

Gross Carrying Value, Indefinite Lived

^[2]

1,008,000

$ 1,008,000

1,008,000

Tradenames & Trademarks | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

1,008,000

In Process Research & Development

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives, Indefinite Lived

^[2]

indefinite

Gross Carrying Value, Indefinite Lived

^[2]

25,000

$ 25,000

25,000

In Process Research & Development | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

$ 25,000

Patents in Process

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives, Indefinite Lived

^[5]

indefinite

Gross Carrying Value, Indefinite Lived

^[5]

$ 579,987

$ 0

[1]	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2013, this license had a remaining net book value of approximately $309,000.
[2]	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2013 an additional $108,910 of costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.
[3]	On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel in the original amount of $2,667,000. In 2012, we booked an impairment charge related to this asset of $946,819. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix® product line and fully impaired the asset. This resulted in an impairment charge of $368,102 which is included in the Company's Statement of Operations.
[4]	On September 1, 2005, we acquired a license from SaluMedica, LLC (SaluMedica) in the original amount of $2,399,000 for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In 2012, we booked an impairment charge related to this asset of $851,676. In the fourth quarter of 2013, the Company made a decision to discontinue marketing the HydroFix® product line and fully impaired the asset. There was no charge to Operations as the asset was fully amortized.
[5]	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Long-Term Debt (Schedule of Debt Instruments) (Details) - USD ($)

Dec. 31, 2013

Dec. 31, 2012

Debt Instrument [Line Items]

Total debt

$ 0

$ 5,313,645

Less unamortized debt discount

(1,301,203)

Less current portion

Long-term portion

4,012,442

5% Convertible Senior Secured Promissory Note

Debt Instrument [Line Items]

Total debt

^[1]

$ 0

$ 5,313,645

[1]

(a)Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052, which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.

Long-Term Debt (Details) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
Long-Term Debt (Details) - USD ($)	Jul. 31, 2012	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	May 17, 2013
Debt Instrument [Line Items]
Warrants, term			5 years
5% Convertible Senior Secured Promissory Note
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)			$ 1.09
Annual interest rate (in hundredths)			5.00%	5.00%	5.00%
Proceeds from issuance of debt				$ 5,000,000	$ 5,000,000
Principal of notes convertible (in shares)					5,000,000
Accrued but unpaid interest (in dollars per share)					$ 1.00
Placement fee			$ 32,800
Placement fee, warrants issued (in shares)			42,400
Warrants, term				5 years
Fair value of placement fee warrants			$ 15,000
Direct costs of sale of notes			$ 47,800
Maturity date				Dec. 31, 2013
5% Convertible Senior Secured Promissory Note \| First Contingent Warrants
Debt Instrument [Line Items]
Percentage of equity securities to be sold for conversion of notes (in hundredths)			25.00%
Warrant exercise price (in dollars per share)			$ 0.01
Warrants vested (in shares)					1,250,000
Additional interest resulting from beneficial conversion feature			$ 2,278,052
5% Convertible Senior Secured Promissory Note \| Second Contingent Warrants
Debt Instrument [Line Items]
Percentage of equity securities to be sold for conversion of notes (in hundredths)			25.00%
Warrant exercise price (in dollars per share)			$ 0.01
Warrants voided (in shares)	1,250,000
Closing trading price of Company stock (in dollars per share)	$ 1.75
Number of consecutive trading days	10 days
5% Convertible Senior Secured Promissory Note \| Chairman and CEO
Debt Instrument [Line Items]
Proceeds from issuance of debt					$ 500,000
Loan Agreement
Debt Instrument [Line Items]
Total amount of debt plus accrued interest		$ 5,272,000
Convertible secured promissory note to common stock (in shares)		5,272,000	532,260
Amortization of debt discount			$ 1,328,000
Loan Agreement \| LIBOR
Debt Instrument [Line Items]
Annual interest rate (in hundredths)						2.00%
Loan Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 3,000,000
Loan Agreement \| Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 1,000,000

Net Income (loss) Per Share (Details) - USD ($)	3 Months Ended												12 Months Ended
Net Income (loss) Per Share (Details) - USD ($)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Computation of basic and diluted net loss per share [Abstract]
Net income (loss)	$ (1,426,938)	$ (307,118)	$ (757,389)	$ (1,620,408)	$ (1,605,283)	$ (4,219,372)	$ (744,069)	$ (1,093,652)	$ (2,577,196)	$ (1,765,723)	$ (2,503,505)	$ (3,347,562)	$ (4,111,853)	$ (7,662,376)	$ (10,193,986)
Denominator for basic earnings per share - weighted average shares													96,285,504	81,646,295	72,450,337
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)													0	0	0
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities													96,285,504	81,646,295	72,450,337
Income (loss) per common share - basic and diluted (in dollars per share)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.04)	$ (0.09)	$ (0.14)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													16,660,776	22,056,948	27,372,173
Outstanding Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													15,375,960	13,614,135	10,333,583
Outstanding Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													1,284,816	3,129,168	9,388,817
Convertible Debt, promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													0	5,313,645	5,007,732
Convertible Line of Credit with Related Party
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													0	0	1,342,726
Convertible Debt, Acquisition
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													0	0	1,299,315

Common Stock Placements (Details) - Common Stock - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2011
Sale of stocks and warrants [Line Items]
Shares issued (in shares)	5,750,000	5,750,000	3,778,321
Share issue price (in dollars per share)	$ 6.80	$ 6.80
Proceeds from shares issued	$ 36,704,000
Legal fees paid for secondary offering	$ 194,000
Executive Officers and Directors
Sale of stocks and warrants [Line Items]
Restricted Period	90 days
Chairman and Chief Executive Officer
Sale of stocks and warrants [Line Items]
Shares issued (in shares)	150,000

Equity (Narrative) (Details)	12 Months Ended
Equity (Narrative) (Details)	Dec. 31, 2013 USD ($) plan $ / shares shares	Dec. 31, 2012 USD ($) $ / shares	Dec. 31, 2011 USD ($) $ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of share-based compensation plans \| plan	3
Outstanding assumed options (in shares) \| shares	375,000
Additional shares authorized by Board of Directors (in shares) \| shares	6,000,000
Shares authorized (in shares) \| shares	22,500,000
Intrinsic value of options exercised \| $	$ 8,864,115	$ 718,978	$ 258,000
Intrinsic value of options vested \| $	3,351,000	$ 1,851,000	$ 1,194,000
Total unrecognized compensation expense \| $	$ 12,052,935
Weighted-average grant date fair value for options granted during the period (in dollars per share) \| $ / shares	$ 3.08	$ 1.07	$ 0.63

Equity (Activity of Stock Options) (Details)

12 Months Ended

Dec. 31, 2013

USD ($)

$ / shares

Number of Shares

Outstanding, beginning of period (in shares) | shares

13,614,135

Granted (in shares) | shares

4,021,000

Exercised (in shares) | shares

(1,958,674)

Unvested options forfeited (in shares) | shares

(265,002)

Vested options expired (in shares) | shares

(35,499)

Outstanding, end of period (in shares) | shares

15,375,960

Vested at end of period (in shares) | shares

6,807,732

Exercisable options, vested and expected to vest (in shares) | shares

15,081,653

^[1]

Weighted- Average Exercise Price

Outstanding, weighted average exercise price, beginning of period (in dollars per share) | $ / shares

$ 1.42

Granted, weighted average exercise price (in dollars per share) | $ / shares

5.31

Exercised, weighted average exercise price (in dollars per share) | $ / shares

1.01

Unvested options forfeited weighted-average exercise price (in dollars per share) | $ / shares

3.47

Vested options expired weighted-average exercise price (in dollars per share) | $ / shares

1.11

Outstanding, weighted average exercise price, end of period (in dollars per share) | $ / shares

2.46

Vested at end of period weighted average exercise price (in dollars per share) | $ / shares

1.33

Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares

$ 2.42

^[1]

Stock options, additional disclosures

Outstanding Options, weighted average remaining contractual term

7 years 8 months 12 days

Vested at end of period weighted average remaining contractual term

6 years 6 months

Vested and expected to vest, weighted average remaining contractual term

7 years 8 months 12 days

^[1]

Outstanding intrinsic value | $

$ 96,614,260

Vested at end of period aggregate intrinsic value | $

50,441,475

Vested and expected to vest, aggregate intrinsic value | $

$ 95,324,825

^[1]

[1]	Includes forfeiture adjusted unvested shares.

Equity (Exercise Price Ranges) (Details)	12 Months Ended
Equity (Exercise Price Ranges) (Details)	Dec. 31, 2013 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options (in shares) \| shares	15,375,960
Outstanding Options, weighted average remaining contractual term	7 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 2.46
Number of exercisable options (in shares) \| shares	6,807,732
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.33
$0.50 - $0.76
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	0.50
Exercise Price Range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) \| shares	1,225,935
Outstanding Options, weighted average remaining contractual term	4 years
Outstanding Options, weighted average exercise price (in dollars per share)	$ 0.65
Number of exercisable options (in shares) \| shares	1,225,935
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.65
$0.87 - $1.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	0.87
Exercise Price Range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) \| shares	6,570,341
Outstanding Options, weighted average remaining contractual term	7 years 7 months 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.20
Number of exercisable options (in shares) \| shares	3,604,469
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.18
$1.40 - $2.29
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	1.40
Exercise Price Range, upper range limit (in dollars per share)	$ 2.29
Number of outstanding options (in shares) \| shares	1,571,700
Outstanding Options, weighted average remaining contractual term	6 years 1 month 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.66
Number of exercisable options (in shares) \| shares	1,321,698
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.66
$2.33 - $3.75
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	2.33
Exercise Price Range, upper range limit (in dollars per share)	$ 3.75
Number of outstanding options (in shares) \| shares	2,091,984
Outstanding Options, weighted average remaining contractual term	8 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 2.77
Number of exercisable options (in shares) \| shares	655,630
Exercisable Options, weighted average exercise price (in dollars per share)	$ 2.77
$3.95 - $6.02
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	3.95
Exercise Price Range, upper range limit (in dollars per share)	$ 6.02
Number of outstanding options (in shares) \| shares	3,435,500
Outstanding Options, weighted average remaining contractual term	9 years 3 months 18 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 5.13
Number of exercisable options (in shares) \| shares	0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.00
$6.04 - $7.93
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	6.04
Exercise Price Range, upper range limit (in dollars per share)	$ 7.93
Number of outstanding options (in shares) \| shares	480,500
Outstanding Options, weighted average remaining contractual term	8 years 10 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 6.61
Number of exercisable options (in shares) \| shares	0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.00

Equity (Summary of Unvested Stock Options) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Number of Shares
Unvested at beginning of year (in shares)	8,377,538
Granted (in shares)	4,021,000
Called/expired (in shares)	(265,002)
Vested (in shares)	(3,565,308)
Unvested at end of year (in shares)	8,568,228
Weighted- Average Grant Date Fair Value
Unvested at beginning of year (in dollars per share)	$ 0.96
Granted (in dollars per share)	3.08
Cancelled/expired (in dollars per share)	2.14
Vested (in dollars per share)	0.94
Unvested at end of year (in dollars per share)	$ 0.96	$ 1.94

Equity (Assumptions) (Details)	12 Months Ended
Equity (Assumptions) (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair value options valuation assumptions [Abstract]
Expected life	6 years	6 years	6 years
Expected dividend yield (in hundredths)	0.00%	0.00%	0.00%
Risk-free interest rate, minimum (in hundredths)	0.85%	0.62%	0.86%
Risk-free interest rate, maximum (in hundredths)	1.88%	1.77%	2.24%
Maximum
Fair value options valuation assumptions [Abstract]
Expected volatility (in hundredths)	64.77%	64.30%	58.10%
Minimum
Fair value options valuation assumptions [Abstract]
Expected volatility (in hundredths)	61.41%	45.70%	57.30%

Equity (Summary of Restricted Stock Awards) (Details) - Restricted Stock - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$ 2,471,000
Expenses expected to be recognized over a weighted-average period	2 years 6 months
Number of Shares
Beginning Balance	7,500	0
Granted	576,550	7,500
Forfeited	(5,000)
Vested	(2,500)	0
Ending Balance	576,550	7,500
Weighted- Average Grant Date Fair Value
Beginning Balance (in dollars per share)	$ 3.49	$ 0.00
Granted (in dollars per share)	5.55	3.49
Forfeited (in dollars per share)	6.60
Vested (in dollars per share)	3.49	0.00
Ending Balance (in dollars per share)	$ 5.53	$ 3.49
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

Equity (Recognized Stock-Based Compensation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation [Abstract]
Share-based compensation expense	$ 6,009,176	$ 2,538,721	$ 1,659,083
Cost of Products Sold
Share-based Compensation [Abstract]
Share-based compensation expense	279,215	97,970	98,366
Research and Development
Share-based Compensation [Abstract]
Share-based compensation expense	417,436	289,341	254,997
Selling, General and Administrative
Share-based Compensation [Abstract]
Share-based compensation expense	$ 5,312,525	$ 2,151,410	$ 1,305,720

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Equity (Warrants) (Details)	12 Months Ended
Equity (Warrants) (Details)	Dec. 31, 2013 $ / shares $ / Unit shares	Dec. 31, 2012 $ / shares $ / Unit shares	Dec. 31, 2011 $ / shares $ / Unit shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, term	5 years
Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants outstanding, beginning of period (in shares)	3,129,168	9,388,817	6,003,924
Warrants voided (in shares)		0
Warrants exercised (in shares)		(325,000)
Warrants outstanding, end of period (in shares)	1,284,816	3,129,168	9,388,817
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants outstanding, beginning of period (in dollars per share) \| $ / Unit	1.04	1.00	1.21
Warrants issued (in dollars per share) \| $ / shares		$ 0.00
Warrants exercised (in dollars per share) \| $ / shares		$ 0.01
Warrants outstanding, end of period (in dollars per share) \| $ / Unit	0.90	1.04	1.00
Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants outstanding, beginning of period (in shares)	0	5,245,484	1,252,990
Warrants voided (in shares)		3,247,741
Warrants exercised (in shares)		0
Warrants outstanding, end of period (in shares)	0	0	5,245,484
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants outstanding, beginning of period (in dollars per share) \| $ / Unit	0.00	0.01	0.01
Warrants issued (in dollars per share) \| $ / shares		$ 0.01
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00
Warrants outstanding, end of period (in dollars per share) \| $ / Unit	0.00	0.00	0.01
Warrants in Connection with Private Placement \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)		1,672,743	1,889,161
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares		$ 0.01	$ 1.50
Warrants in Connection with Private Placement \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)		1,672,743	1,889,162
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares		$ 0.01	$ 0.01
Warrants Issued in Connection with Convertible Promissory Notes \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			203,332
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 1.50
Warrants Issued in Connection with Convertible Promissory Notes \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			203,332
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 0.01
Warrants In Connection With Line of Credit with Related Party \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)		325,000	0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares		$ 0.01	$ 0.00
Warrants In Connection With Line of Credit with Related Party \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)		325,000	650,000
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares		$ 0.01	$ 0.01
Warrants Issued in Connection with Senior Secured Promissory Notes \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			1,250,000
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 0.01
Warrants Issued in Connection with Senior Secured Promissory Notes \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			1,250,000
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 0.01
Placement Agent \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			42,400
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 1.09
Placement Agent \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants issued (in shares)			0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants issued (in dollars per share) \| $ / shares			$ 0.00
Contingent warrants related to convertible note \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		(1,249,750)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.01
Contingent warrants related to convertible note \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00
Contingent warrants related to private placement of common stock \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		(1,608,802)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.01
Contingent warrants related to private placement of common stock \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00
Callable warrants \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		(3,288,733)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 1.50
Callable warrants \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00
Other \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)	(1,844,352)	(1,703,568)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares	$ 1.14	$ 0.63
Other \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)	0	0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares	$ 0.00	$ 0.00
Warrants expired \| Warrants
Warrants, Number of Warrants [Roll Forward]
Expired warrants (in shares)		(10,000)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants expired (in dollars per share) \| $ / shares		$ 1.00
Warrants expired \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Expired warrants (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants expired (in dollars per share) \| $ / shares		$ 0.00
Warrants Redeemed for Cashless Exercises \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		(14,789)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.53
Warrants Redeemed for Cashless Exercises \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00
Repurchase of callable warrants \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		(56,750)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 1.50
Repurchase of callable warrants \| Contingent Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares)		0
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / shares		$ 0.00

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets and liabilities [Abstract]
Accrued liabilities	$ 1,404,000	$ (125,000)
Beneficial conversion feature on convertible financial instruments	0	(449,000)
Intangible assets	1,021,000	1,117,000
Property and equipment	(507,000)	89,000
R&D tax credit carryforwards	1,369,000	1,407,356
Stock Compensation	2,151,000	213,000
Adjust accrued earn-out liability	0	567,947
Charitable Contributions	1,000	3,000
Patent fees	142,000	6,000
Net operating loss	14,663,000	15,539,000
Net deferred tax assets	20,244,000	18,368,303
Valuation allowance	(20,244,000)	(18,368,303)
Deferred tax assets and liabilities, net of valuation allowance	$ 0	$ 0
Reconciliation of the Federal statutory income tax rate [Abstract]
Federal statutory rate (in hundredths)	34.00%	34.00%
State taxes, net of federal benefit (in hundredths)	(2.48%)	3.40%
Permanent items & other (in hundredths)	12.73%	0.65%
Valuation allowance (in hundredths)	(46.73%)	(38.05%)
Effective income tax rate (in hundredths)	(2.48%)	0.00%
Operating Loss Carryforwards [Line Items]
Deferred tax assets	$ 20,244,000	$ 18,368,303
Operating loss carry forwards, expiration dates	2027 and 2033
Federal
Deferred tax assets and liabilities [Abstract]
Net deferred tax assets	$ 12,533,000
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	36,861,000
Deferred tax assets	12,533,000
State
Deferred tax assets and liabilities [Abstract]
Net deferred tax assets	2,130,000
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	30,036,000
Deferred tax assets	$ 2,130,000

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash paid for interest	$ 36,202	$ 13,322	$ 15,456
Income taxes paid	61,129	0	0
Purchases of equipment financed through capital leases	355,144	84,650	0
Stock issuance of 167,086 shares in lieu of Directors' fees	0	$ 184,653	0
Stock issuance in lieu of Directors' fees (in shares)		167,086
Deferred financing costs	27,236	$ 20,449	0
Convertible Secured Promissory Notes issued in conjunction with the acquisition of Surgical Biologics	0	0	1,250,000
Warrants issued for placement fees associated with Senior Secured Promissory Notes	0	0	14,885
Beneficial conversion related to related party	0	514,456	80,000
Stock issuance of 5,250,000 shares in conjunction with acquisition of Surgical Biologics	0	0	$ 7,087,500
Stock issued in conjunction with acquisition of Surgical Biologics (in shares)			5,250,000
Beneficial conversion related to convertible debt issued with regard to acquisition of Surgical Biologics	0	0	$ 437,500
Stock issuance in connection of Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares for 2012	$ 5,792,330	$ 3,185,223	0
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt of 5,272,004 shares in 2013 and 406,664 shares in 2011	$ 5,272,004	$ 0	$ 406,663
Stock issued for convertible debt (in shares)	5,272,004		406,664
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	$ 0	$ 1,403,630	$ 0
Stock issued during period, shares, issued for payment of Line of Credit with related party (shares)		1,403,630
Stock issuance of 216,085 shares for exercise of cashless warrants	0	$ 216	0
Shares issued for Cashless Exercise (in shares)		216,085
Secured Promissory Notes related to acquisition of Surgical Biologics	$ 0	$ 893,267	$ 2,278,052
Stock issued related to acquisition of Surgical Biologics (in shares)	893,267	893,267	893,267
Tenant improvement incentive	$ 996,866	$ 0	$ 0
Legal fees paid for public offering	101,694	0	0
Accounts payable
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	30,100	0	0
Accrued expenses
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	$ 62,396	$ 0	$ 0

Related Party Transactions (Details) - USD ($)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Related party expense

$ 70,141

$ 201,812

$ 92,565

Hybrid debt instrument

Interest expense

^[1]

3,232

Line of credit

Interest expense

^[2]

103,630

42,726

Convertible senior secured promissory notes

Interest expense

^[3]

50,000

4,507

Office space lease

Related party expense

^[4]

70,141

48,182

41,000

Aircraft use

Related party expense

^[5]

$ 0

$ 1,100

[1]	interest of $3,232 related to convertible promissory notes issued in October 2010 to the Chairman of the Board and CEO and two other members of the Board of Directors
[2]	interest of $103,630 for 2012 and $42,726 for 2011, respectively related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011
[3]	interest of $50,000 for 2012 and $4,507 for 2011, respectively related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011
[4]	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO for $70,141 for 2013 $48,182 for 2012 and $41,000 for 2011, respectively
[5]	payments related to aircraft use from an entity owned by a former member of the Board of Directors

401k Plan (Details)	12 Months Ended
401k Plan (Details)	Dec. 31, 2013 USD ($)
Compensation and Retirement Disclosure [Abstract]
Minimum age require to qualify for pension plan	21 years
Minimum service period require to qualify for pension plan	3 months
Maximum wages deferred (in hundredths)	100.00%
Maximum eligible wages deferred by participants per year	$ 17,500
Minimum age for additional contribution beyond normal plan	50 years
Defined benefit plan, contributions by plan participants	$ 5,500
Employer matching contribution (in hundredths)	6.00%

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
2014	$ 869,841
2015	1,300,289
2016	1,339,418
2017	1,379,877
2018	1,421,135
Thereafter	119,581
Total Contractual commitments	6,430,141
Rent and operating leases expense	1,000,000	$ 485,000	$ 488,000
Letters of Credit
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
Standby letters of credit	$ 525,000

Quarterly Financial Data (Unaudited) (Details) - USD ($)	3 Months Ended												12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 17,993,790	$ 16,115,708	$ 13,514,743	$ 11,556,493	$ 10,509,663	$ 7,954,046	$ 4,884,256	$ 3,705,808	$ 2,635,466	$ 2,152,094	$ 1,929,399	$ 1,043,487	$ 59,180,734	$ 27,053,773	$ 7,760,446
Gross margin	14,882,616	14,002,270	11,316,261	9,651,473	8,820,402	6,528,710	3,769,330	2,746,953	1,719,125	1,265,584	1,084,458	333,370	49,852,620	21,865,395	4,402,537
Net income (loss)	$ (1,426,938)	$ (307,118)	$ (757,389)	$ (1,620,408)	$ (1,605,283)	$ (4,219,372)	$ (744,069)	$ (1,093,652)	$ (2,577,196)	$ (1,765,723)	$ (2,503,505)	$ (3,347,562)	$ (4,111,853)	$ (7,662,376)	$ (10,193,986)
Net income (loss) per common share - basic and diluted (in dollars per share)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.04)	$ (0.09)	$ (0.14)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 49,000	$ 19,000	$ 21,000
Additions charged to Expense or Revenue	391,000	57,000	58,000
Deductions and write-offs	(33,000)	(27,000)	(60,000)
Balance at End of Year	407,000	49,000	19,000
Allowance for product returns
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	89,000	88,000	39,000
Additions charged to Expense or Revenue	917,000	394,000	189,000
Deductions and write-offs	(791,000)	(393,000)	(140,000)
Balance at End of Year	215,000	89,000	88,000
Allowance for obsolescence
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	159,000	53,000	29,000
Additions charged to Expense or Revenue	213,000	106,000	30,000
Deductions and write-offs	(50,000)	0	(6,000)
Balance at End of Year	$ 322,000	$ 159,000	$ 53,000